Google Alert - "Myeloproliferative neoplasms" OR "polycythemia vera" OR myelofibrosis OR "essential thrombocythemia" google.com

Shilpa Biologicals, mAbTree Achieve FDA Milestone for Rare Blood Cancer Treatment

google.com·9w

Prelude Therapeutics files to offer up to $25 million in stock through Jefferies

google.com·9w

Navigating the Expanding Landscape of Myelofibrosis Treatment

google.com·9w

Shilpa Biologicals and mAbTree Biologics Secure Orphan Drug Designation from U.S. FDA

google.com·10w

Myelofibrosis Market: Strong Pharma Growth Forecast Through 2034 - DelveInsight

google.com·10w

Myelofibrosis Market: Strong Pharma Growth Forecast Through 2034

google.com·10w

Jensen, Robert M. 'Bob' | Obituaries Cedar Rapids, Iowa City

google.com·10w

Syntara: Pioneering Myelofibrosis Therapy with a Multi-Pipeline Future

google.com·10w

SNDX: Robust product launches and expanding clinical programs position the company for ...

google.com·10w

FDA Accepts NDA for Rusfertide and Grants Priority Review in Polycythemia Vera

google.com·10w

Betta joins Revolution in pan-RAS inhibition | ApexOnco - Clinical Trials news and analysis

google.com·10w

FDA Accepts NDA for Rusfertide and Grants Priority Review in Polycythemia Vera

google.com·10w

ANTX: Epetraborole enters phase 2 for PV with rapid trial start, broad pipeline progress, and ...

google.com·10w

Strategies for Anemia Management in Myelofibrosis

google.com·10w

Clinical Judgment Essential in Defining Anemia in Myelofibrosis

google.com·10w

Prelude Therapeutics Reports Full Year 2025 Financial Results and Provides Program ...

google.com·10w

Prelude Therapeutics Reports Full Year 2025 Financial Results and Provides Program ...

google.com·10w

IRON: Phase III data for bitopertin and key pipeline readouts are expected by year-end

google.com·10w

Rodman & Renshaw initiates Karyopharm stock with buy rating

google.com·10w

PIM Inhibitor Shows Promise in High-Risk Myelofibrosis

google.com·10w

Log in to enable infinite scrolling